Data gathered: November 15
Alternative Data for Ovid Therapeutics
Alternative Data | Value | 3m Change | Trend | Benchmark | |
---|---|---|---|---|---|
Job Posts | N/A | Sign up | Sign up | Sign up | |
Sentiment | 75 | Sign up | Sign up | Sign up | |
Webpage traffic | 2,000 | Sign up | Sign up | Sign up | |
Employee Rating | 86 | Sign up | Sign up | Sign up | |
Google Trends | 5 | Sign up | Sign up | Sign up | |
Patents | 75 | Sign up | Sign up | Sign up | |
4chan Mentions | N/A | Sign up | Sign up | Sign up | |
Facebook Engagement | 3 | Sign up | Sign up | Sign up | |
Facebook Followers | 2,354 | Sign up | Sign up | Sign up | |
Instagram Followers | 576 | Sign up | Sign up | Sign up | |
Reddit Mentions | N/A | Sign up | Sign up | Sign up | |
Stocktwits Mentions | 1 | Sign up | Sign up | Sign up | |
Stocktwits Subscribers | 5,808 | Sign up | Sign up | Sign up | |
Twitter Followers | 1,606 | Sign up | Sign up | Sign up | |
Twitter Mentions | 23 | Sign up | Sign up | Sign up | |
Youtube Subscribers | 524 | Sign up | Sign up | Sign up | |
News Mentions | N/A | Sign up | Sign up | Sign up | |
Customer reviews | N/A | Sign up | Sign up | Sign up | |
Business Outlook | 52 | Sign up | Sign up | Sign up | |
Linkedin Employees | 43 | Sign up | Sign up | Sign up |
About Ovid Therapeutics
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States.
Price | $1.15 |
Target Price | Sign up |
Volume | 135,980 |
Market Cap | $87M |
Year Range | $0.7 - $3.34 |
Dividend Yield | 0% |
Analyst Rating | 86% buy |
Industry | Biotechnology |
In the news
Ovid Therapeutics (OVID) Reports Q3 Loss, Tops Revenue EstimatesNovember 11 - Yahoo |
|
Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial ResultsNovember 11 - Yahoo |
|
Ovid Therapeutics : November Corporate DeckNovember 11 - Finnhub |
|
Ovid Therapeutics to Host Investor EventOctober 30 - Yahoo |
|
Ovid Therapeutics Inc. (NASDAQ:OVID) Receives Average Recommendation of “Moderate Buy” from AnalystsOctober 29 - ETF Daily News |
|
Ovid Therapeutics Inc. (NASDAQ:OVID) Receives Average Recommendation of "Moderate Buy" from AnalystsOctober 29 - Biztoc.com |
Financial performance View All
Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
---|---|---|---|---|---|---|
Q3 '24 | 170,000 | 5.6M | -5.4M | -14M | -13M | 0.000 |
Q2 '24 | 170,000 | 8.1M | -8M | 8.5M | -20M | 0.120 |
Q1 '24 | 150,000 | 7.2M | -7.1M | -12M | -17M | -0.170 |
Q4 '23 | 140,000 | 7.7M | -7.6M | -15M | -18M | -0.220 |
Q3 '23 | 110,000 | 6.8M | -6.7M | -11M | -12M | -0.160 |
Insider Transactions View All
LEVIN JEREMY M filed to buy 3,616,715 shares at $2.8. March 20 '24 |
Similar companies
Read more about Ovid Therapeutics (OVID) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Ovid Therapeutics?
The Market Cap of Ovid Therapeutics is $87M.
What is the current stock price of Ovid Therapeutics?
Currently, the price of one share of Ovid Therapeutics stock is $1.15.
How can I analyze the OVID stock price chart for investment decisions?
The OVID stock price chart above provides a comprehensive visual representation of Ovid Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Ovid Therapeutics shares. Our platform offers an up-to-date OVID stock price chart, along with technical data analysis and alternative data insights.
Does OVID offer dividends to its shareholders?
As of our latest update, Ovid Therapeutics (OVID) does not offer dividends to its shareholders. Investors interested in Ovid Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Ovid Therapeutics?
Some of the similar stocks of Ovid Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.